Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. · MIST (NASDAQ) · Montreal, QC · Pharmaceuticals
Latest R&D (CAD)
$25.3M
Period ended 2025-12-31
Revenue (CAD)
—
Intensity —
R&D by fiscal period
2025
$25.3M
2024
$19.7M
2023
$41.9M
2022
$51.8M
2021
$48.5M
2020
$46.3M
2019
$55.7M
2018
$21.8M
| Period end | R&D (CAD) | Revenue (CAD) | Native R&D | Form | Source |
|---|---|---|---|---|---|
| 2025-12-31 | $25,311,362 | — | $18,108,000 USD | 10-K | SEC EDGAR |
| 2024-12-31 | $19,666,219 | — | $14,357,000 USD | 10-K | SEC EDGAR |
| 2023-12-31 | $41,910,884 | — | $31,052,000 USD | 10-K | SEC EDGAR |
| 2022-12-31 | $51,829,478 | — | $39,829,000 USD | 10-K | SEC EDGAR |
| 2021-12-31 | $48,474,099 | — | $38,671,000 USD | 10-K | SEC EDGAR |
| 2020-12-31 | $46,265,652 | — | $34,488,000 USD | 10-K | SEC EDGAR |
| 2019-12-31 | $55,709,897 | — | $41,985,000 USD | 10-K | SEC EDGAR |
| 2018-12-31 | $21,831,249 | — | $16,849,000 USD | 10-K/A | SEC EDGAR |